Risankizumab redefines Crohn's treatment after ustekinumab failure

Conventional Crohn's disease biologic sequencing typically follows drug class transitions: Anti-tumor necrosis factor, anti-integrin, and anti-cytokine therapies. However, a landmark real-world study by Colwill et al disrupts this paradigm, revealing exceptional efficacy within the cytokine pathway, specifically with risankizumab following ustekinumab. This study asserts these provocative findings demand a critical reappraisal of treatment algorithms, while contextualizing them within the current evidence landscape. It will critically appraise the study's impressive remission rates and favorable safety profile, contrasting them with alternative switch strategies and exploring the compelling mechanistic rationale for sequential interleukin-23 blockade. The discussion will center on integrating this preliminary evidence into clinical decision-making, advocating for further research to define its place in a new treatment hierarchy.